Document is current
Any future updates will be listed below
-
Authors
Hvorecny, Kelli L. https://orcid.org/0000-0002-4609-6170
Interlandi, Gianluca
Veth, Tim S. https://orcid.org/0000-0002-2561-5437
Aprikian, Pavel
Manchenko, Anna https://orcid.org/0000-0001-5982-4504
Tchesnokova, Veronika L.
Dickinson, Miles S.
Quispe, Joel D.
Riley, Nicholas M. https://orcid.org/0000-0002-1536-2966
Klevit, Rachel E. https://orcid.org/0000-0002-3476-969X
Magala, Pearl
Sokurenko, Evgeni V.
Kollman, Justin M. https://orcid.org/0000-0002-0350-5827
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35 GM149542)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R00 GM147304)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (K99 GM141364)
U.S. Department of Health & Human Services | National Institutes of Health (S10 OD023476)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (F32 AI145111)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01 AI171570)
National Science Foundation (TG-BIO240017)
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (R01 AI171570)
- License Information
-
More Information
Article History
Received: 31 January 2025
Accepted: 17 October 2025
First Online: 26 November 2025
Competing interests
: E.V.S. and V.T. hold US10722580B2 patent ‘Compositions and methods for treatment and prevention of uropathogenic E. coli infection’ that include therapeutic use of mAb475 and mAb926. NMR receives support from Thermo Fisher Scientific under a nondisclosure agreement and is a consultant for Tegmine Therapeutics, Cartography Biosciences, and Augment Biologics. The remaining authors declare no competing interests.
